Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8996556 | 1.00 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4852674 | 1.00 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4856316 | 0.91 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2KCNA5TACR3 | |
| SCHEMBL4848178 | 0.91 | PKM (0.54) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4855940 | 0.91 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4855845 | 0.91 | PKM (0.48) | MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4846798 | 0.90 | TDP1 (0.53) | MEN1KMT2ACASR | |
| SCHEMBL4852606 | 0.90 | PLA2G1B (0.55) | MEN1KMT2AALDH1A1CASR | |
| SCHEMBL4855579 | 0.90 | ALDH1A1 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4850988 | 0.90 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594843-B1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative | TAKASAGO PERFUMERY CO LTD (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8188307-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL COPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7601842-B2 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036149-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | AADAT, KMO, ALDH7A1 | MEN1 1376/4885KMT2A 837/4885SMN1; SMN2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.